GSK vs INCY
GSK plc vs Incyte — AI-powered side-by-side comparison
GSK
GSK plc
64
Insufficient Data
VS
| Metric | GSK | INCY |
|---|
| AI Score |
64
|
72
|
| Price |
$50.91
|
$121.08
|
| P/E Ratio |
15.80×
|
14.89×
|
| ROE |
35.0%
|
24.9%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
73.3%
|
92.6%
|
| Debt / Equity |
1.03×
|
0.01×
|
| Dividend Yield |
3.5%
|
0.0%
|
| RSI (14) |
39.2
|
56.2
|
| Beta |
0.3
|
0.769
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for GSK versus INCY.
INCY leads by 8 points.
INCY scores 72/100 (Buy) versus GSK at 64/100 (Insufficient Data).
GSK Committee View
67% agreement
3 analysts
Some positive signals exist — vix regime is low -- calm backdrop supports risk-taking — but they are not yet strong enough to justify a Buy. The committee is monitoring for confirmation.
Bull Case
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
- News sentiment is positive (+0.27 across 20 articles, 14d) — News
Bear Case
- MACD histogram negative -- bearish momentum — Technical
INCY Committee View
100% agreement
6 analysts
The primary driver is revenue growing 26.9% yoy -- genuine top-line momentum. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 29.6% shows genuine earnings power backing the valuation — Value
- Revenue growing 26.9% YoY -- genuine top-line momentum — Growth
- EPS growing 80.3% YoY — Growth
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 75 -- overbought on the larger timeframe too — Technical